TEVA
Teva Pharmaceutical Industries Limited American Depositary Shares
$34.67
+$0.59(+1.75%)
62
Overall
80
Value
58
Tech
50
Quality
Market Cap
$39.67B
Volume
2.95M
52W Range
$14.99 - $37.35
Target Price
$39.45
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $21.9B | $22.4B | $18.3B | $16.9B | $16.7B | $15.9B | $14.9B | $15.8B | $16.5B | $17.3B | ||
| Total Revenue | $21.9B | $22.4B | $18.3B | $16.9B | $16.7B | $15.9B | $14.9B | $15.8B | $16.5B | $17.3B | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $10.0B | $11.6B | $10.0B | $9.4B | $8.9B | $8.3B | $8.0B | $8.2B | $8.5B | $8.3B | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $11.9B | $10.8B | $8.3B | $7.5B | $7.7B | $7.6B | $7.0B | $7.6B | $8.1B | $8.9B | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $4.9B | $1.3B | $3.4B | $1.5B | $2.6B | $2.9B | $4.2B | $4.4B | $4.7B | $5.0B | ||
| Research & Development | $2.1B | $1.8B | $1.2B | $1.0B | $997.0M | $967.0M | $838.0M | $953.0M | $998.0M | $1.0B | ||
| Research Expense | $2.1B | $1.8B | $1.2B | $1.0B | $997.0M | $967.0M | $838.0M | $953.0M | $998.0M | $1.0B | ||
| Selling, General & Administrative | $5.1B | $5.0B | $4.2B | $3.8B | $3.7B | $3.5B | $3.4B | $3.5B | $3.7B | $4.0B | ||
| Selling & Marketing Expenses | $3.9B | $3.7B | $2.9B | $2.6B | $2.5B | $2.4B | $2.3B | $2.3B | $2.5B | $2.7B | ||
| General & Administrative Expenses | $1.3B | $1.3B | $1.3B | $1.2B | $1.2B | $1.1B | $1.2B | $1.2B | $1.2B | $1.3B | ||
| Promotion & Advertising | $312.0M | $318.0M | $256.0M | $213.0M | $225.0M | $246.0M | $168.0M | -- | -- | -- | ||
| Salaries & Wages | $-2.3B | $-5.6B | $-1.8B | $-3.2B | $-2.0B | $-1.5B | -- | -- | -- | -- | ||
| Depreciation & Amortization | $1.5B | $2.1B | $676.0M | $609.0M | $537.0M | $528.0M | $576.0M | $537.0M | $471.0M | -- | ||
| Depreciation & Amortization | $1.5B | $2.1B | $676.0M | $609.0M | $537.0M | $528.0M | $576.0M | -- | -- | -- | ||
| Amortization | $44.4B | $28.4B | $1.1B | $1.1B | $21.6B | $20.8B | $18.4B | $17.8B | $15.7B | -- | ||
| Other Operating Expenses | $-71.0M | $-26.0M | $-291.0M | $-76.0M | $-40.0M | $-98.0M | $-107.0M | $-49.0M | $-14.0M | $18.0M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $2.2B | $-17.5B | $-1.6B | $-443.0M | $-3.6B | $1.7B | $-2.2B | $433.0M | $-303.0M | $2.2B | ||
| EBITDA | $2.9B | $-15.4B | $166.0M | $1.3B | $-1.9B | $2.9B | $-2.2B | $531.0M | $-224.0M | $2.2B | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $546.0M | $875.0M | $920.0M | $881.0M | $901.0M | $891.0M | $930.0M | -- | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $-546.0M | $-875.0M | $-920.0M | $-881.0M | $-901.0M | $-891.0M | $991.0M | $-1.0B | $-1.1B | -- | ||
| Gain on Sale of Securities | $51.0M | $84.0M | $39.0M | $41.0M | $104.0M | $31.0M | $11.0M | -- | -- | -- | ||
| Other Income/Expense | $553.0M | $-301.0M | $1.0B | $835.0M | $696.0M | $1.0B | $-4.9B | $1.1B | $980.0M | $919.0M | ||
| Other Special Charges | $-561.0M | $304.0M | $-959.0M | $-822.0M | $-834.0M | $-1.1B | $-966.0M | $-1.1B | $-981.0M | $-934.0M | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | $245.0M | $535.0M | $488.0M | $199.0M | $120.0M | $133.0M | $146.0M | -- | -- | -- | ||
| Special Income Charges | $-900.0M | $-17.1B | $-3.0B | $-1.5B | $-4.6B | $-850.0M | $-2.0B | $-700.0M | $-1.3B | -- | ||
| Impairment of Capital Assets | $900.0M | $17.1B | $3.0B | $139.0M | $4.6B | -- | $2.0B | $700.0M | $1.3B | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $1.4B | $-17.5B | $-1.7B | $-384.0M | $-3.5B | $1.5B | $-2.2B | $-622.0M | $-1.3B | $1.2B | ||
| Pre-Tax Income | $824.0M | $-18.4B | $-2.6B | $-1.3B | $-4.4B | $658.0M | $-3.2B | $-624.0M | $-1.3B | $1.2B | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $521.0M | $-1.9B | $-195.0M | $-278.0M | $-168.0M | $211.0M | $-643.0M | $-7.0M | $676.0M | $-180.0M | ||
| NET INCOME | ||||||||||||
| Net Income | $329.0M | $-16.3B | $-2.1B | $-999.0M | $-4.0B | $417.0M | $-2.4B | $-559.0M | $-1.6B | $1.4B | ||
| Net Income (Continuing Operations) | $329.0M | $-16.3B | $-2.1B | $-999.0M | $-4.0B | $417.0M | $-2.5B | $-615.0M | $-2.0B | $1.4B | ||
| Net Income (Discontinued Operations) | $329.0M | $-16.3B | $-2.1B | $-999.0M | $-4.0B | $417.0M | $-2.4B | $-559.0M | $-1.6B | $1.4B | ||
| Net Income (Common Stockholders) | $68.0M | $-16.5B | $-2.4B | $-999.0M | $92.0M | $417.0M | $-2.4B | $-559.0M | $-1.6B | $1.4B | ||
| Normalized Income | -- | -- | $1.5B | $1.6B | $1.6B | -- | -- | -- | -- | $1.1B | ||
| TOTALS | ||||||||||||
| Total Expenses | $15.0B | $12.8B | $13.3B | $10.9B | $11.5B | $11.2B | $12.1B | $12.6B | $13.2B | $13.3B | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $955.0M | $1.0B | $1.0K | $1.1B | $1.1B | $1.1B | $1.1B | $1.1B | $1.1B | -- | ||
| Average Shares Outstanding (Diluted) | $961.0M | $1.0B | $1.0K | $1.1B | $1.1B | $1.1B | $1.1B | $1.1B | $1.1B | -- | ||
| Shares Outstanding | $1.1B | $1.1B | $1.1B | $1.1B | $1.1B | $1.1B | $1.1B | $1.1B | $1.1B | $1.1B | ||
| Basic EPS | $0.07 | $-16.26 | $-2.35 | $-0.91 | $-3.64 | $0.38 | $-2.12 | $-0.50 | $-1.45 | -- | ||
| Basic EPS (Continuing Operations) | $0.07 | $-16.26 | $-2.35 | $-0.91 | $-3.64 | $0.38 | $-2.12 | $-0.50 | $-1.45 | -- | ||
| Diluted EPS | $0.07 | $-16.26 | $-2.35 | $-0.91 | $-3.64 | $0.38 | $-2.12 | $-0.50 | $-1.45 | -- | ||
| Diluted EPS (Continuing Operations) | $0.07 | $-16.26 | $-2.35 | $-0.91 | $-3.64 | $0.38 | $-2.12 | $-0.50 | $-1.45 | -- | ||
| Dividend Per Share | $1.156 | $1.36 | -- | -- | -- | -- | -- | -- | -- | -- | ||
| OTHER METRICS | ||||||||||||
| Accrued Preferred Stock Dividends | $261.0M | $260.0M | $249.0M | -- | -- | -- | -- | -- | -- | -- | ||
| Acquisition Expense | $261.0M | $105.0M | $13.0M | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings from equity interest | $8.0M | $-3.0M | $-71.0M | $-13.0M | $138.0M | $9.0M | $21.0M | $2.0M | $1.0M | $15.0M | ||
| Earnings From Equity Interest Net Of Tax | $8.0M | $-3.0M | $-71.0M | $-13.0M | $138.0M | $9.0M | $21.0M | $2.0M | $1.0M | $15.0M | ||
| Gain On Sale Of Business | -- | -- | $67.0M | $50.0M | $8.0M | $51.0M | $46.0M | $3.0M | $15.0M | $-22.0M | ||
| Gain On Sale Of P P E | -- | -- | $9.0M | $-1.0M | $11.0M | $7.0M | $18.0M | $25.0M | $2.0M | $2.0M | ||
| Minority Interests | $18.0M | $184.0M | $322.0M | $2.0M | $109.0M | $-39.0M | $53.0M | $56.0M | $320.0M | $-7.0M | ||
| Net Income Discontinuous Operations | -- | -- | -- | -- | -- | -- | -- | -- | $281.0M | -- | ||
| Non Recurring Operation Expense | -- | -- | $-1.2B | $1.2B | $60.0M | $717.0M | $2.1B | -- | -- | -- | ||
| Other Gand A | $1.3B | $1.3B | $1.3B | $1.2B | $1.2B | $1.1B | $1.2B | $1.2B | $1.2B | $1.3B | ||
| Other Impairment Of Capital Assets | $746.0M | $3.8B | $2.0B | $1.6B | $1.5B | $424.0M | $355.0M | -- | -- | -- | ||
| Preferred Stock Dividends | $261.0M | $260.0M | $249.0M | -- | -- | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | $164.0M | $200.0M | $175.0M | -- | -- | -- | -- | -- | -- | -- | ||
| Restruct | $245.0M | $535.0M | $488.0M | $199.0M | $120.0M | $133.0M | $146.0M | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TEVA | $34.67 | +1.7% | 2.95M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Teva Pharmaceutical Industries Limited American Depositary Shares Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW